BofA raised the firm’s price target on Alnylam (ALNY) to $328 from $325 and keeps a Buy rating on the shares. The firm updated models in smid-cap biotech as part of a Q1 earnings preview.

Pushkal Garg; Chief Medical Officer, Executive Vice President - Development and Medical Affairs; Alnylam Pharmaceuticals Inc Jeffrey Poulton; Chief Financial Officer, Executive Vice President ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $57.5 million in its first quarter. The Cambridge, Massachusetts-based ...

(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced that results from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM ...